0001829126-23-004053.txt : 20230609
0001829126-23-004053.hdr.sgml : 20230609
20230609163515
ACCESSION NUMBER: 0001829126-23-004053
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230606
FILED AS OF DATE: 20230609
DATE AS OF CHANGE: 20230609
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Leider Harry L.
CENTRAL INDEX KEY: 0001888273
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-55008
FILM NUMBER: 231005895
MAIL ADDRESS:
STREET 1: C/O GELESIS, INC.
STREET 2: 501 BOYLSTON STREET, SUITE 6102
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Organicell Regenerative Medicine, Inc.
CENTRAL INDEX KEY: 0001557376
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 474180540
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1031
BUSINESS ADDRESS:
STREET 1: 3321 COLLEGE AVENUE
STREET 2: SUITE 246
CITY: DAVIE
STATE: FL
ZIP: 33314
BUSINESS PHONE: 888-963-7881
MAIL ADDRESS:
STREET 1: 3321 COLLEGE AVENUE
STREET 2: SUITE 246
CITY: DAVIE
STATE: FL
ZIP: 33314
FORMER COMPANY:
FORMER CONFORMED NAME: Biotech Products Services & Research, Inc.
DATE OF NAME CHANGE: 20150917
FORMER COMPANY:
FORMER CONFORMED NAME: BESPOKE TRICYCLES INC
DATE OF NAME CHANGE: 20120831
3
1
ownership.xml
FORM 3
X0206
3
2023-06-06
0
0001557376
Organicell Regenerative Medicine, Inc.
OCEL
0001888273
Leider Harry L.
3321 COLLEGE AVENUE
SUITE 246
DAVIE
FL
33314
1
1
0
0
CEO and Director
Options to Purchase Common Stock
0.012
2023-09-06
2028-06-06
Common Stock, par value $0.001 per share
57000000
D
Represents an option to purchase common stock granted to the Reporting Person on June 6, 2023 under the issuer's Equity Incentive Plan (the "Plan"). The option vests in equal quarterly installments over a three-year period from the date of grant, is contingent upon the Reporting Person's continued employment by the issuer and is otherwise subject to the terms and conditions of the Plan. In the event of a "change in control" or the achievement of certain milestones, vesting of the option may be accelerated.
/s/ Harry Leider
2023-06-09